
Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) released its first-quarter financial results, showcasing operational progress and updates across its clinical pipeline.
Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs Read More